{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-076833","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.262490+00:00","generated_at":"2026-05-15T23:45:12.329259+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Revelation Biosciences reports Q4 and FY2025 results; cash $10.7M, net loss $8.9M","bullets":["Cash and cash equivalents $10.7M as of Dec 31, 2025 vs $6.5M in 2024; net proceeds of $6.7M from warrant inducement in January 2026","Net loss for FY2025 was $8.9 million ($23.95 per share) vs $15.0 million ($1,052.16 per share) in FY2024","Announced positive results from PRIME clinical study in late-stage chronic kidney disease patients","Reached agreement with FDA on a single adaptive Phase 2/3 study for Gemini to treat acute kidney injury","Clinical data on Gemini for AKI and CKD to be presented at International Conference on Advances in Critical Care Nephrology (March 29-April 1, 2026)"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-076833","json":"https://secwatch.observer/filing/0001193125-26-076833.json","markdown":"https://secwatch.observer/filing/0001193125-26-076833.md","text":"https://secwatch.observer/filing/0001193125-26-076833.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526076833/0001193125-26-076833-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526076833/revb-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T23:45:12.329259+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}